Fiche publication
Date publication
février 2018
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr LEJEUNE Catherine
Tous les auteurs :
Lejeune C, Lueza B, Bonastre J,
Lien Pubmed
Résumé
In oncology, as in other fields of medicine, international multicentre clinical trials came into being so as to include a sufficient number of subjects to investigate a clinical situation. The existence of tight budgetary constraints and the desire to make the best use of the resources available have resulted in the development of economic evaluations associated with these trials, which, thanks to their level of evidence and their size, provide particularly relevant material. Nonetheless, economic evaluations alongside international clinical trials raise specific questions of methodology with regard to both the design and the analysis of the results. Indeed, the costs of goods and services consumed, the types and quantities of resources, and medical practices vary from one country to another and within an individual country. Economic data from the different countries involved must be available so as to study and to take into account this variability, and appropriate techniques for cost estimations and analysis must be implemented to aggregate the results from several countries. From a review of the literature, the aim of this work was to provide an overview of the specific methodological features of economic evaluations alongside international clinical trials: analysis of efficacy data from several countries, collection of resources and real costs, methods to establish the monetary value of resources, methods to aggregate results accounting for the trial effect.
Mots clés
Clinical Trials as Topic, economics, Cost-Benefit Analysis, Humans, Internationality, Medical Oncology, economics, Multicenter Studies as Topic, economics, Resource Allocation
Référence
Bull Cancer. 2018 Feb;105(2):204-211
